Roche’s Xofluza Receives FDA Approval for Reducing Influenza Transmission in Phase III Study
Roche (SWX: ROG; OTCMKTS: RHHBY) has announced that its antiviral drug Xofluza (baloxavir marboxil) has...
J&J’s Rybrevant Secures FDA Approval for EGFR/c-MET Non-Small Cell Lung Cancer Treatment
Johnson & Johnson (J&J; NYSE: JNJ)has announced that the US Food and Drug Administration (FDA)...
Beijing’s Apollobio Receives NMPA Approval for HPV Therapeutic Vaccine VGX-3100
Beijing’s Apollobio, has announced that the National Medical Products Administration (NMPA) has granted market approval...
Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study
China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its...
Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has...
Jiangsu Hengrui Pharmaceuticals’ SHR-1701 Combo Therapy for Gastric Cancer Accepted for Review by China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
JiCui Cell Therapy Forms Partnership with Fosun Kite to Advance Bispecific CAR-T Cell Therapy Industrialization
JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute...
Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D...
CSPC Pharmaceutical Group Appoints Dr. Liu Yongjun as Group CEO and Global R&D President
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Sinopharm Holding Appoints New Chairman and President Following Leadership Changes
Sinopharm Holding (HKG: 1099) has announced significant changes in its leadership with the approval of...
China’s NMPA Releases Standards for Brain-Computer Interface Medical Devices
The National Medical Products Administration (NMPA) in China has issued a notification confirming the establishment...
Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first...
Ocumension Therapeutics’ Zerviate Receives Marketing Approval in China for Allergic Conjunctivitis Treatment
Ocumension Therapeutics (HKG: 1477), a leading ophthalmology specialist in China, has announced that its histamine...
Organon Inks Deal to Acquire Dermavant, Bolstering Dermatology Portfolio with Vtama Cream
US healthcare company Organon (NYSE: OGN) has announced a definitive agreement to acquire Dermavant, a...
MSD’s Keytruda Secures FDA Approval for First-Line Mesothelioma Treatment in Combination with Chemotherapy
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that the US Food and...
AstraZeneca’s Fasenra Secures FDA Nod for EGPA Treatment, Strengthening Rare Disease Portfolio
UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has announced that the US Food and...
Fidson Healthcare Partners with Chinese Entities to Establish Drug Plant in Nigeria
Nigeria-based pharmaceutical manufacturer Fidson Healthcare Plc has entered into a strategic partnership with Jiansu Aidea...
MGI Tech Joins Forces with Dasa to Enhance Precision Medicine in Brazil Through Advanced Genomic Sequencing
MGI Tech Co., Ltd, a leading gene sequencing company based in China, has announced a...
AstraZeneca’s Tagrisso Achieves Milestones in Phase III LAURA Study for EGFR-mutated NSCLC at ESMO 2024
Global pharmaceutical company AstraZeneca (AZ, NASDAQ: AZN, LON: AZN) has reported updated results from the...
Keymed Biosciences’ Stapokibart Receives First Prescription in China for IL-4Rα Targeting Therapy
China-based biotech company Keymed Biosciences Inc. (HKG: 2162) has reached a significant milestone with its...